top of page


Público·1 miembro

How To Buy Gw Pharmaceuticals Stock

Two years ago, I highlighted the very first company to have an FDA approved cannabis product. GW Pharmaceuticals (NASDAQ:GWPH) had just gained approval for their epilepsy drug. There was momentum with their drug being accepted by insurers and Medicaid as well as patients that needed them. Since then, several more states have changed their status with regards to accepting cannabis-derived medicine via Medicaid. Revenues have grown steadily over the past quarters. Earnings per share are still negative, though. But the company has just posted above-expectations revenues and earnings and has guided that they see continued growth with their product. As well, they continue to invest in their future with a strong pipeline of drugs. With this success, perhaps, finally, GW Pharmaceuticals stock will begin to move higher over a longer period of time.

how to buy gw pharmaceuticals stock

I did an analysis of this company about 2 solid years ago where I thought that GWPH was a buy. Every stock is a buy. But that does not mean you will be profitable after having done so. GWPH is one of those stocks. This was the heyday of the cannabis industry where a lot of money was pouring into a new, fledgling industry. Canadian cannabis had just been legalized and a whole lot of companies started producing a whole lot of cannabis. But Canadian dispensaries were slow to roll out and these various companies ended up holding a lot of excess inventory.

View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Shares in GW Pharma quickly rose to match the price promised in the deal, while Jazz stock traded flat. Shares in Zogenix, a biotech developing a competing treatment to Epidiolex for Dravet syndrome, rose by nearly 10%.

Wall Street didn't see the deal coming. Jazz focuses on sleeping disorders. But the deal places a wealthy premium on GWPH stock and diminishes the likelihood of other bidders, Needham analyst Serge Belanger said in a report to clients.

Under the terms of the deal, Jazz will pay $220 per American depositary share. That's split in $200 per ADS in cash and $20 in Jazz ordinary shares. The entire deal values GWPH stock at $7.2 billion, or $6.7 billion net of GW Pharma's cash.

In addition to Epidiolex, Jazz will add a growing pipeline of cannabis-based drugs. Investors in GWPH stock are watching nabiximols, a potential treatment for spasticity-related conditions. The company expects to have study results beginning in mid-2021.

The deal also sent shares of fellow epilepsy-focused biotech companies flying. Zogenix (ZGNX) stock roared up 9.5% to 21.55. Xenon Pharmaceuticals (XENE) popped 5.4% to 17.16. Zynerba Pharmaceuticals (ZYNE) surged 27.4% to 4.53.

This merger is a cash-plus-stock acquisition. This is a fully taxable merger with stock and cash as the merger consideration. For tax purposes this is treated as a sale of GW Pharmaceuticals for the value of the cash and stock received. Some of the proceeds from the sale (the value of the stock received) is used to purchase Jazz Pharmaceuticals. All the information below is from the information available from the DEFM14A filed with the SEC by GWPH. Here is a link to this filing

Drug developer GW Pharmaceuticals more than doubled after it reported positive results from a late-stage study of its drug Epidiolex, an experimental seizure disorder treatment derived from a marijuana extract. The stock surged $46.25, or 120 percent, to $84.71. Zynerba Pharmaceuticals, which is studying a drug based on synthetic compounds derived from cannabis, climbed $12.59, or 149 percent, to $21.03. 041b061a72

Acerca de

¡Bienvenido al grupo! Puedes conectarte con otros miembros, ...
bottom of page